Goserelin Acetate as Treatment for Recurrent Endometrial Carcinoma

Robert F. Asbury, Virginia L. Brunetto, Roger B. Lee, +2

American Journal of Clinical Oncology

Goserelin AcetateMedicineCancer ManagementGynecologyPathology +8

Hepatic veno-occlusive disease due to DTIC

Robert F. Asbury, Susan N. Rosenthal, M E Descalzi, +2

Cancer

Hepatic DisordersAutoimmune DiseaseHepatologyHepatic Veno-occlusive DiseaseLiver Physiology +12

Weekly paclitaxel in advanced non[ndash ]small cell lung cancer

Alex Y. Chang, Jonathan Rubins, Robert F. Asbury, +2

Seminars in Oncology

MedicineWeekly PaclitaxelCancer TreatmentOncologyRadiation Oncology +1

Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists.

Gary R. Morrow, Robert F. Asbury, Sharon Hammon, +2

Health Psychology

Behavioral TreatmentClinical PsychologistsPharmacotherapyHealth PsychologyCancer Patients +16

Treatment of metastatic breast cancer with aminoglutethimide

Robert F. Asbury, Richard Bakemeier, E Fölsch, +3

Cancer

Seventy-three WomenMetastatic Breast CancerOncologyComplete ResponsesBreast Oncology +7

A Phase I Study of Weekly Cisplatin and Whole Abdominal Radiation for the Treatment of Stage III and IV Endometrial Carcinoma: A Gynecologic Oncology Group Pilot Study

Susan A. Reisinger, Robert F. Asbury, Shu‐Yuan Liao, +1

Gynecologic Oncology

Weekly CisplatinRadiation MedicineRadiation TherapyMedicineGynecology +6

Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancer.

A. Y. Chang, László G. Boros, Robert F. Asbury, +2

PubMed

Comparing the effectiveness of behavioral treatment for chemotherapy-induced nausea and vomiting when administered by oncologists, oncology nurses, and clinical psychologists.

Gary R. Morrow, Robert F. Asbury, Sharon Hammon, +4

Health Psychology

NursingBehavioral TreatmentBehavioral MedicineChemotherapy-induced NauseaMedicine +5

Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.

A. Y. Chang, László G. Boros, George C. Garrow, +1

PubMed

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer

William Tester, Kyung Mann Kim, Robert L. Krigel, +6

Lung Cancer

CytokineTumor MicroenvironmentLung InflammationMedicineAdvanced Lung Disease +7